Aleafia Health: Featured Cannabis Stock

Cultivation: 13,000 kg per year. Ramping up to 115,000 kg per year after new license approvals.

Distribution
Direct sales: N/A
Store networks: Joint venture with Flying High brands to distribute their products
Supply agreements: In October 2019, Aleafia Health made an announcement regarding the termination of a supply agreement with Aphria. Aphria failed to meet its supply obligations and the issue is referred to as confidential arbitration.

Registered patients: 70,000.

CEO: Geoffrey Benic
CFO: Benjamin Ferdinand

Geoffrey Benic, CEO of Aleafia Health, has more than 15 years of experience in the logistics and supply chain industry implementing a vertical integration growth strategy. Benjamin Ferdinand, CFO of Aleafia Health, brings vast experience of fundraising having a background in the investment banking industry.

Aleafia Health: Strong Recommendation

Aleafia Health is a vertically integrated company focused on offering cannabis-related health and wellness products. Aleafia Health produces cannabis capsules, oil, and sprays from their three licensed cannabis production facilities in Canada.

Aleafia Health was listed in the 50 top-performing companies for 2019 amongst all 2,000 TSX Venture Exchange listed companies.

Aleafia Health is focused on expanding its network of medical cannabis education centers and clinics across Northern America and Europe.

Geoffrey Benic, CEO of Aleafia Health, has more than 15 years of experience in the logistics and supply chain industry implementing a vertical integration growth strategy. Benjamin Ferdinand, CFO of Aleafia Health, brings vast experience of fundraising with a background in the investment banking industry.

Aleafia is in the process of increasing its extraction capacity from 13,000 kg to 115,000 kg after their pending license is approved. Aleafia Health is supporting its patient acquisition and data gathering initiatives through its portfolio of cannabis medical clinics under an integrated model. Aleafia Health has built a portfolio of formulations and brands for recreational and medical cannabis markets.

Will Aleafia’s stock price improve in the long term? Very Likely.

By December 31, 2019, Aleafia Health had cash equivalents and short-term investments were $41.2 million, which is sufficient to cover the cost of operations in 2020.

Aleafia Health is very responsive to market conditions as they recently started the “last-mile home” delivery service of medical cannabis during the COVID-19 pandemic in the spring of 2020.

Aleafia Health revenues grew 27% in the fourth quarter as to $6 million as compared to last quarter however they faced a net loss of $9.8 million as compared to a net loss of $1.9 million in the third quarter. The rise in net loss was due to gain non-cash expenses related to the fair value of biological assets and deferred income tax expense.

For these reasons, we suggest Aleafia Health, at or near its current price of $0.30 a share, can be a good investment opportunity.

Aleafia Health: Featured Cannabis Stock